VIDEO: With Ryzumvi approval, ‘no reason to not dilate’
Click Here to Manage Email Alerts
LAS VEGAS — The recent FDA approval of Ryzumvi for the reversal of drug-induced mydriasis has created the opportunity to perform more dilated, comprehensive eye exams, according to Paul M. Karpecki, OD, FAAO.
In this Healio video from Vision Expo West, Karpecki, who practices at the Kentucky Eye Institute in Lexington and is a faculty member at the University of Pikeville, said that in the clinical trials of Ryzumvi (phentolamine ophthalmic solution 0.75%, Ocuphire Pharma and Viatris), patients who were pharmacologically dilated needed to be within 0.2 mm of their original pupil size after Ryzumvi administration.
“Ryzumvi met that statistically significant improvement over the vehicle at every time point, from 1 hour through to 24 hours,” he said. “That’s a fascinating opportunity; now we have no reason to not dilate.”
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts